Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): February 15, 2002

                           ORASURE TECHNOLOGIES, INC.
                 (Exact name of issuer as specified in charter)

       DELAWARE                    1-10492                    36-4370966
    (State or Other              (Commission              (I.R.S. Employer
     Jurisdiction                    file                   Identification
  of Incorporation or               number)                    Number)

                               150 Webster Street
                          Bethlehem, Pennsylvania 18015
                    (Address of principal executive offices)

                                 (610) 882-1820
              (Registrant's telephone number, including area code)

Item 5 - Other Events.

On February 15, 2002,  OraSure  Technologies,  Inc.  (the  "Company" or "OraSure
Technologies")  announced that it would report revenues of $32.6 million for the
full year 2001 and $8.1 million for the quarter ended  December 31, 2001.  After
excluding  revenues in 2000 from the  discontinued  Serum  Western Blot product,
these  amounts  represent  increases of 20 percent and 9 percent,  respectively,
over revenues reported for the same periods a year ago.

The Company's net loss was  approximately  $3.7 million or $(0.10) per share for
the full year 2001 and $2.3 million or $(0.06) per share for the fourth quarter.
These  results  represent an  improvement  from the net loss of $12.7 million or
$(0.36)  per share for the full  year 2000 and the net loss of $3.7  million  or
$(0.10) per share in the fourth quarter of 2000,  which included  merger-related
charges of $7.6 million and $1.7 million, respectively.

The  increase  in  revenues  was  primarily  the  result  of  increased   market
penetration of the Company's oral fluid substance  abuse and infectious  disease
testing products and increased license and product  development  revenue.  These
increases were  partially  offset by a decline in revenues in the insurance risk
assessment  market  due  to  customer  inventory   consolidation  and  increased
efficiencies at certain customers as well as declines in other product lines due
to generally soft market conditions.

The Company's gross margin for the full year 2001 improved from 61% to 62%, as a
result of lower  material  costs,  productivity  gains and  higher  license  and
development  revenues,  which were  partially  offset by the  recognition  of an
inventory  reserve in the fourth quarter of $0.6 million  related to OraQuick(R)
HIV tests  manufactured for sale to the Company's African  distributor.  For the
fourth  quarter of 2001,  the Company's  gross margin  declined from 63% to 53%,
primarily as a result of the OraQuick(R)  inventory reserve  established  during
that  period.   Because  of  the  repeated  failure  by  the  Company's  African
distributor to meet its contractually-required minimum purchase commitments, the
Company  recently   reevaluated  its  international   strategy  for  OraQuick(R)
distribution and terminated its agreement with this  distributor.  The resulting
inventory  reserve was  required  in light of this  action and serious  concerns
surrounding  the  product's  remaining  shelf-life  in relation to the Company's
ability to rapidly  establish a new  distribution  channel in Africa to sell the

Operating expenses for the fourth quarter,  excluding  merger-related charges in
2000,  declined 4% from a year ago to approximately  $6.8 million.  For the full
year ended  December  31, 2001,  operating  expenses,  excluding  merger-related
charges, remained flat at approximately $24 million.

Item 9 - Regulation FD Disclosure.

On February 15, 2002, the Company  announced that it continues to target revenue
growth of up to 30% for 2002 to approximately $42 million,  and profitability in
the  second  half of 2002 and for the year as a whole.  However,  the  Company's
ability to achieve these results is dependent on several factors,  including the
timely receipt of regulatory  approvals,  market  acceptance of new products and
the timely startup of several new distributors for its products.

The  foregoing  discussion  contains  certain  forward-looking  statements  with
respect to revenues, earnings, products,  regulatory filings and markets. Actual
results  could be  significantly  different.  Factors that could affect  results
include  the  ability  to  market  products;  impact of  competitors,  competing
products and technology  changes;  ability to develop,  commercialize and market
new products; market acceptance of oral fluid testing products and up-converting
phosphor technology products; ability to fund research and development and other
projects and  operations;  ability to obtain and timing of  obtaining  necessary
regulatory  approvals;   ability  to  develop  product  distribution   channels;
uncertainty  relating to patent  protection  and potential  patent  infringement
claims; ability to enter into international manufacturing agreements;  obstacles
to  international  marketing  and  manufacturing  of  products;  ability to sell
products internationally;  loss or impairment of sources of capital; exposure to
product  liability  and other  types of  litigation;  changes in  international,
federal or state laws and regulations;  changes in relationships  with strategic
partners  and reliance on strategic  partners  for the  performance  of critical
activities under collaborative arrangements;  changes in accounting practices or
interpretation  of accounting  requirements;  customer  inventory  practices and
consolidations;  equipment  failures and ability to obtain  needed raw materials
and components;  the impact of terrorist  attacks and civil unrest;  and general
business,  political  and  economic  conditions.  These  and other  factors  are
discussed  more fully in the  Securities  and  Exchange  Commission  (the "SEC")
filings of OraSure  Technologies,  including its  registration  statements,  its
Annual  Report on Form 10-K for the year ended  December 31, 2000,  and its most
recent Quarterly Report on Form 10-Q. Although  forward-looking  statements help
to provide complete  information about future prospects,  readers should keep in
mind that  forward-looking  statements may not be reliable.  The forward-looking
statements  are  made as of the date of this  Report  and  OraSure  Technologies
undertakes no duty to update these statements.


            Pursuant to the  requirements  of the Securities and Exchange Act of
1934,  the  Registrant has duly caused this Report to be signed on its behalf by
the undersigned, hereunto duly authorized.

                                    OraSure Technologies, Inc.

Date: February 19, 2002             By: /s/ Michael G. Gausling
                                          Michael G. Gausling
                                          President and Chief Executive Officer